Pharmaceutical Packaging for Patient Safety

Pharmaceutical packaging is a critical part of medication safety.

As MedSafety Week 2026 calls on patients and healthcare professionals to report suspected side effects, the industry also needs to examine how packaging materials, container systems, and product information help prevent medication errors, protect product quality, and support safe use throughout the supply chain.

Image

Medicine Packaging Is Part of Product Quality

Packaging materials can influence a medicine’s lifecycle long after formulation and manufacturing are complete.

Covering pharmaceutical packaging, material performance, contamination risks, regulatory standards, and emerging technologies, packaging materials for patient safety span four main material groups: Glass, plastics, metals, and rubber.

Each offers useful properties, but each also introduces risks that manufacturers must understand and control.

This is important during MedSafety Week every first week of November, because a reported adverse reaction is not always explained by the active ingredient alone. Packaging can affect a medicine’s stability, composition, sterility, and delivered dose.

A material that interacts with a formulation, allows moisture to enter, or fails to maintain a reliable seal can compromise the product before it reaches the patient.

Packaging also has a role in preventing physical damage during distribution.

Secondary packaging protects containers from impact, vibration, and handling damage. Primary packaging provides the immediate barrier around the medicine. For sterile products, that barrier must preserve container integrity and protect against microbial entry.

Packaging is therefore a product quality control, not simply a presentation or logistics component. Its design and performance should remain connected to formulation development, manufacturing controls, storage conditions, and distribution strategy.

The relationship becomes more important as products become more complex. Biologics, injectables, sensitive formulations, and products that require cold-chain distribution can place specific demands on container materials and closure systems.

A packaging choice that works for one formulation cannot automatically be assumed suitable for another.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Material Choice Creates Different Risks

Manufacturers need to assess packaging materials according to their chemical, physical, and biological properties.

There is no universally suitable material. Selection depends on the product, its formulation, route of administration, storage conditions, and intended shelf life.

Glass offers stability, but still needs assessment

Glass remains widely used, particularly for injectable medicines. Borosilicate glass offers strong chemical durability, resistance to thermal shock, and low thermal expansion. These properties make it suitable for products that require robust protection and sterilisation.

However, glass is not entirely inert. Certain formulations can interact with the internal surface, leading to the release of alkaline substances or glass particles. These changes can affect pH, introduce particulate contamination, and alter product quality.

Manufacturers therefore need to assess the compatibility of the specific glass container with the medicine it holds.

Container selection, surface quality, processing, and storage conditions all matter.

Plastics offer flexibility, but migration remains a concern

Polyethylene, polypropylene, and polyvinyl chloride are common in pharmaceutical packaging. Their flexibility, manufacturing versatility, and cost make them useful across many dosage forms.

The risk is that plastic components can release additives into the product.

Plasticisers, stabilisers, antioxidants, and other substances used during production may migrate during storage.

There is also di(2-ethylhexyl) phthalate (DEHP), which can migrate from certain PVC infusion bags and create particular health concerns for vulnerable populations.

Plastics can also allow oxygen and moisture to pass through more readily than some alternative materials. This can affect the stability of medicines that are sensitive to environmental exposure.

Barrier polymers, including PVDC and EVOH, can help address some of these limitations.

The practical lesson is that material flexibility does not remove the need for product-specific compatibility testing.

Manufacturers must understand both the polymer and the additives used to produce the final packaging component.

Metals and rubber perform essential functions

Aluminium foil provides a strong barrier against light, oxygen, and moisture. It is widely used in blister packaging for tablets and capsules.

Metal containers also offer strength and can suit aerosols, sprays, and selected formulations.

However, elemental impurities from raw materials or manufacturing processes can enter medicines if the material is not appropriately controlled.

Internal coatings and surface treatments also require assessment where they form part of the product-contact system.

Rubber is especially important in closures. Stoppers and seals protect vials and other containers from external contamination. They must maintain a reliable seal while allowing practical access to the medicine, including through needle penetration where required.

Yet rubber can introduce extractables, leachables, and subvisible particles. Then there is the need to control sulphur content in certain butyl rubber stoppers because material inconsistencies can affect quality.

These details are important for injectables, where closure performance forms part of the sterile packaging system.

Image

Packaging Performance Must Be Controlled Across the Drug Lifecycle

The material itself is only one part of the risk.

Packaging performance depends on how components are manufactured, assembled, filled, sealed, stored, and transported.

There are several mechanisms through which packaging can affect medication safety:

• Barrier failure: Oxygen, water vapour or light can enter the package and degrade sensitive medicines. For example, vitamin C, aspirin, and chlorpromazine all illustrate different forms of environmental sensitivity.
• Mechanical damage: Weak packaging can crack, deform, or leak during handling, transport, and storage.
• Chemical migration: Additives or other packaging constituents can move into the medicine and alter its quality.
• Adsorption: Packaging materials can absorb active ingredients or other formulation components, reducing the amount available to the patient.
• Microbial contamination: Poor hygiene or inadequate environmental controls during packaging-material production can introduce microorganisms into components that contact medicines.

These risks have direct operational consequences.

A damaged closure can compromise a sterile product, while a material that absorbs an active ingredient can affect delivered potency, and moisture ingress can change a tablet’s stability.

Each problem can lead to rejected batches, product investigations, recalls, or patient harm.

Manufacturers should therefore assess packaging as part of the product’s wider control strategy.

This includes supplier qualification, incoming material testing, component specifications, compatibility studies, extractables, and leachables assessment, container-closure integrity, and appropriate microbial controls.

Additionally, clean manufacturing environments are vital for packaging components.

Hygiene practices, equipment condition, and process controls can all affect contamination risk.

This makes packaging suppliers an important part of the pharmaceutical quality network, not simply external providers of commodity materials.

Regulatory expectations reflect this responsibility.

The U.S. Pharmacopeia includes dedicated chapters covering plastic packaging materials and systems, while the European Pharmacopoeia and Japanese Pharmacopoeia also set requirements for packaging materials and containers.

These standards address material identity, performance, and suitability for pharmaceutical use.

In August 2026, the U.S. Food and Drug Administration (FDA) also issued a draft guidance on container closure systems for human drugs and biological products.

The FDA’s draft guidance sets out principles for evaluating the quality of these systems, including where packaging components form part of a combination product. The draft guidance reinforces the importance of assessing the complete system rather than treating individual components in isolation.

For Manufacturing teams, packaging qualification should not end when a supplier is approved. Changes in material composition, manufacturing processes, component suppliers, or storage conditions can alter performance.

Change control and ongoing supplier oversight must account for these risks.

Packaging also has to perform under real distribution conditions. Temperature, humidity, vibration, and transit time can expose weaknesses that may not appear during initial testing.

Pharmatica’s Insights into the pharmaceutical cold-chain optimisation explores why packaging, monitoring, and transport must work together to protect sensitive medicines.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

Smart and Sustainable Packaging Need Evidence

Intelligent packaging, nanomaterials, and sustainable materials are all new important areas of development for better pharma manufacturing.

These technologies could improve product protection, support traceability, and reduce environmental impact. Their adoption, however, must preserve the basic requirements of pharmaceutical quality.

Nanomaterials are attracting interest because their high surface area and other properties can improve barrier performance, mechanical strength, ultraviolet protection, or antimicrobial activity. These features could help address weaknesses in conventional packaging materials.

Image

But new material properties also create new questions.

Manufacturers need to understand whether nanoparticles or related components can migrate into a medicine, how they behave during storage, and whether they introduce toxicological or compatibility concerns. Novelty alone does not establish suitability.

Intelligent or “smart” packaging offers a different opportunity. Systems that support product identification, anti-counterfeiting, measurement, or quality monitoring could help manufacturers and patients manage medicines more safely.

In principle, smart features could make it easier to detect changes in product condition or identify a product moving through an unauthorised supply route.

However, there is still a long way to go before these technologies are ready for routine pharmaceutical use. Their performance needs to be demonstrated in the context of specific products and packaging systems.

Any digital feature must also provide reliable information and fit within the relevant quality and regulatory framework.

Sustainable packaging presents a similar balance. Biodegradable and bio-derived materials could reduce dependence on conventional plastics and lower environmental impact. Yet a more sustainable material is not automatically a safer pharmaceutical material.

It must still protect the medicine against moisture, oxygen, light, and contamination. It must remain compatible with the formulation and withstand manufacturing, storage, and transport.

Environmental impact improvement cannot come at the expense of product integrity.

For manufacturers, this means evaluating sustainability through a product-specific risk assessment. A material that reduces waste but shortens shelf life or increases product loss may create a different environmental burden elsewhere in the supply chain.

The same principle applies to new packaging formats.

Development teams should involve quality, regulatory, procurement, and manufacturing specialists early, so that material innovation is assessed against the full lifecycle of the medicine.

Packaging Is a Supply Chain and Patient Safety Responsibility

MedSafety Week 2026 runs from 2 to 8 November under the message “Side effects: Don't ignore them, report them.”

The campaign, coordinated by the Uppsala Monitoring Centre, brings together medicines regulators and other organisations to encourage reporting of suspected side effects. More than 130 organisations across over 120 countries are participating.

The UK MHRA campaign information also encourages reporting of suspected problems involving medical devices and other healthcare products through the Yellow Card scheme.

Reporting helps regulators build a wider picture of medicine safety.

Packaging quality contributes to that picture by influencing whether a product remains stable, uncontaminated, and suitable for use. The two activities serve different purposes, but they support the same patient-safety objective.

The campaign is a practical reminder that packaging decisions belong in manufacturing and supply chain strategy.

Therefore, procurement teams need visibility into material composition and supplier controls and quality teams need evidence that components remain suitable for their intended use.

Manufacturing teams need processes that protect packaging integrity, while distribution teams need conditions that preserve it.

This requires stronger coordination across the product lifecycle.

Image

Pharmatica’s Insights into integrated pharmaceutical operations and supply chain management examines why manufacturing, procurement, quality, and logistics cannot operate as disconnected functions.

The same principle applies to packaging. Its performance depends on decisions made across all these areas.

Manufacturers should also connect packaging improvements with wider quality systems to uphold continuous improvement efforts.

Supplier performance, deviations, complaints, stability results, and product quality trends can help identify recurring weaknesses and guide better material selection.

The strategic priority is to select materials and systems that protect each medicine, demonstrate consistent performance, and support reliable supply.

At Pharmatica, we examine the technologies, quality systems, and operational decisions shaping pharmaceutical Manufacturing and Supply Chains. Our Insights connect material innovation, regulatory expectations, and production strategy to the patient outcomes that matter.

Pharmatica: Insight. Connection. Impact.